Abstract Objective APPEASE is a phase I study to assess the safety. dosing. and efficacy of rivoceranib (a selective. small-molecule inhibitor of VEGFR2) in combination with pembrolizumab. https://medicalwarehouses.shop/product-category/intermittent-closed-system-catheters/